Interventions to improve inpatient osteoporosis management following first osteoporotic fracture: the PREVENT project
- 209 Downloads
To establish a protocol for the treatment of fragility fractures in the hospital setting based on treatment of osteoporosis.
Materials and methods
An intervention protocol was implemented in patients with fragility fractures based on (1) indicating the diagnosis of osteoporotic fracture in the summary of discharge; (2) “lifestyle recommendations”; and (3) therapy for osteoporosis. Thirty-one hospitals were involved and they were informed of the importance of protocol compliance. In the first phase, a retrospective study was conducted to establish the number of low-energy fractures treated and the percentage of them that had complied with the protocol (n = 887). Then, prospectively, the same data were collected for the patients managed for 1 year (n = 6,826) in three sections of 4-month intervals.
The percentage of compliance increased from 8.2 to 57.2% in the first point, from 12.6 to 42.4% in the second, and from 10.3 to 43.2% in the third.
The implementation of programs to improve osteoporosis treatment is very useful for ensuring adherence in the management of osteoporosis following admission due to fragility fracture.
KeywordsOsteoporotic fractures Osteoporosis treatment Secondary prevention
Financial support for this study was obtained from Merck Sharp and Dohme, Spain.
- 1.Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541PubMedCrossRefGoogle Scholar
- 18.NIH consensus guidelines: osteoporosis prevention, diagnosis, and therapy (2000) NIH Consens Statement 17:1–45Google Scholar
- 19.NOF physician’s guide to prevention and treatment of osteoporosis (1999) National Osteoporosis Foundation, WashingtonGoogle Scholar
- 23.Robinson CM, Royds M, Abraham A, McQueen MM, Court-Brown CM, Christie J (2002) Refractures in patients at least 45 years old. A prospective analysis of 22,060 patients. J Bone Joint Surg A 84:1528–1533Google Scholar
- 25.The National Institute for Health and Clinical Excellence (2005) Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology Appraisal 87, January. www.nice.org.uk
- 27.Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 38:1236–1240Google Scholar